All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sylvester Attracts World’s Top Epigenetics Experts for Fifth Biennial Miami Epigenetics and Cancer Symposium

December 19th 2022

Top epigenetics researchers from around the world gathered in South Beach for the Fifth Biennial Miami Epigenetics and Cancer Symposium, hosted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

FDA Expands Approval for Cytalux Imaging for Lung Cancer Detection

December 19th 2022

The FDA has approved a new indication for pafolacianine to aid surgeons in detecting lung cancer lesions in adult patients with known or suspected lung cancer.

European Commission Recommends Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

December 19th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval for the use of trastuzumab deruxtecan monotherapy for adults with unresectable or metastatic HER2-low breast cancer.

Anti-CEACAM5 ADC Could Represent the Next Targeted Therapy in Advanced Nonsquamous NSCLC

December 19th 2022

Alexander Spira, MD, PhD, FACP, discusses the rationale for targeting CEACAM5 in NSCLC, how tusamitamab ravtansine could provide encouraging frontline responses in the CEACAM5-positive, nonsquamous population, and enrollment challenges faced by ongoing clinical trials.

Chemoimmunotherapy Regimens Improve Long-term Outcomes in Small Cell Lung Cancer

December 18th 2022

Stephen V. Liu, MD, discusses the effect of the FDA approval of atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in small cell lung cancer.

Sacituzumab Govitecan, Trastuzumab Deruxtecan Highlight Expanding Role of ADCs in TNBC

December 17th 2022

Nour Abuhadra, MD, discusses what the data from DESTINY-Breast04 means for trastuzumab deruxtecan in the triple-negative breast cancer space and future areas of research for antibody-drug conjugates in this disease.

Bioequivalence Study Results Showcase Reduced Variability With Dasatinib ASD Formulation

December 16th 2022

Leif Stenke, MD, PhD, discusses the role XS004 may have in future clinical development in chronic myeloid leukemia.

FDA Approves Nadofaragene Firadenovec for High-risk Non–Muscle Invasive Bladder Cancer

December 16th 2022

The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Sidney Kimmel Cancer Center Appoints Dr Alessandro Fatatis Associate Director for Basic Research

December 16th 2022

Alessandro Fatatis, MD, PhD, has been named Associate Director for Basic Research at Jefferson Health’s Sidney Kimmel Cancer Center.

Frontline Zolbetuximab Plus CAPOX Meets PFS, OS End Points in Claudin 18.2+ Gastric or GEJ Cancers

December 16th 2022

The addition of zolbetuximab to capecitabine and oxaliplatin resulted in a statistically significant improvement in progression-free survival and overall survival vs placebo/CAPOX in patients with Claudin 18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal cancers, meeting the primary and secondary end points of the phase 3 GLOW trial.

Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer

December 16th 2022

The use of an individualized starting dose of niraparib led to a trend toward improved overall survival as maintenance therapy vs placebo in Chinese patients with platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status, according to data from the phase 3 NORA trial.

How to Improve Care for LGBTQI+ Patients With Cancer

December 16th 2022

As more and more people in the United States identify as lesbian, gay, bisexual, transgender, queer, intersex, or other sexual orientation or gender minority, the population of LGBTQI+ cancer survivors is becoming uniquely heterogeneous.

Advancements in Immunotherapy Expand and Improve the Treatment Landscape for MCL

December 16th 2022

Joshua Brody, MD, discussed significant updates in MCL treatment presented at the 2022 ASH Annual Meeting, including results from the phase 1/2 BRUIN trial of pirtobrutinib, follow-up data from the phase 2 ZUMA-7 trial on CAR T-cell therapies, and next steps to expand the development of immunotherapies in this disease.

Biomarker Testing Informs Individualized Diagnosis and Treatment of Low- to Intermediate-Risk AML

December 16th 2022

Alexander E. Perl, MD, MS, discusses the implications of the updated ELN guidelines, how genetic testing guides treatment in this disease, and ongoing research investigating novel AML targets such as NPM1 mutations or KMT2A translocations.

Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rate, Is Cost Neutral in HER2+ Breast Cancer in Real-World Setting

December 15th 2022

Neoadjuvant chemotherapy with dual HER2-blockade of pertuzumab and trastuzumab is well tolerated and increases the rate of pathological complete response in patients with HER2-positive breast cancer compared with regimens that contain trastuzumab only, while being neutral on drug cost.

Fox Chase Researcher Receives American Cancer Society Grant to Study Synthetic Targets for Tumor Drug Delivery

December 15th 2022

Swayam Prabha, MBA, PhD was recently awarded a $792,000 American Cancer Society research scholar grant to investigate new methods for treating lung cancer.

PD-L1 Status Could Help Inform Patient Selection for IO-Based Therapy in HNSCC

December 15th 2022

Ranee Mehra, MD, discusses the significance of 5-year follow-up data and the subgroup analysis from KEYNOTE-048, the benefits and limitations of IO therapy in head and neck squamous cell carcinoma, and research aiming to expand the role of IO combination regimens in this space.

FDA Approves Updated Labeling for Capecitabine Tablets

December 15th 2022

The FDA has approved updated labeling for capecitabine tablets (Xeloda) under an initiative aimed to ensure labeling information is clinically meaningful and scientifically up to date.

Tisagenlecleucel Shows Promise in Relapsed/Refractory Aggressive B-Cell NHL and Comorbidities in Real-World Setting

December 15th 2022

Tisagenlecleucel elicited durable efficacy and a favorable long-term safety profile in the real-world setting of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC

December 15th 2022

The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.